Patents by Inventor Suzanne Hendrix

Suzanne Hendrix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL METHODS, DOSING REGIMES AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20080051460
    Abstract: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 ?g per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
    Type: Application
    Filed: May 2, 2007
    Publication date: February 28, 2008
    Applicant: Myriad Genetics, Incorporated
    Inventors: Adrian Hobden, Kenton Zavitz, Gary Mather, Suzanne Hendrix
  • TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20080033045
    Abstract: The invention relates to the treatment of psychiatric disorders.
    Type: Application
    Filed: July 9, 2007
    Publication date: February 7, 2008
    Applicant: Myriad Genetics, Incorporated
    Inventors: Mark Laughlin, Kenton Zavitz, Suzanne Hendrix
  • Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease
    Publication number: 20070293576
    Abstract: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 ?g per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
    Type: Application
    Filed: May 8, 2007
    Publication date: December 20, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Adrian Hobden, Kenton Zavitz, Gary Mather, Suzanne Hendrix
  • Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease
    Publication number: 20070238787
    Abstract: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 ?g per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
    Type: Application
    Filed: February 28, 2007
    Publication date: October 11, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Adrian Hobden, Kenton Zavitz, Gary Mather, Suzanne Hendrix
  • Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease
    Publication number: 20070238786
    Abstract: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 ?g per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
    Type: Application
    Filed: March 1, 2007
    Publication date: October 11, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Adrian Hobden, Kenton Zavitz, Gary Mather, Suzanne Hendrix
  • Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
    Publication number: 20050042284
    Abstract: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 ?g per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
    Type: Application
    Filed: July 12, 2004
    Publication date: February 24, 2005
    Applicant: Myriad Genetics, Incorporated
    Inventors: Adrian Hobden, Kenton Zavitz, Gary Mather, Suzanne Hendrix